[1] Brochot E, Demey B, Aubry A, et al. Epidemiology and dynamics of BK polyomavirus replication after kidney transplantation[J]. Pathogens, 2024, 13: 1-8. doi: 10.3390/pathogens13040315. [2] Wilhelm M, Geng A, Schaub S, et al. Posoleucel for BK polyomavirus in kidney transplant recipients[J]. J Am Soc Nephrol, 2024, 35: 1784-1785. doi: 10.1681/ASN.0000000000000500. [3] Kien TQ, Toan PQ, Nghia PB, et al. Genomic mutations of BK polyomavirus in patients after kidney transplanta-tion: a cross-sectional study in vietnam[J]. J Clin Med, 2022, 11: 1-6. doi: 10.3390/jcm11092544. [4] 王凯,李明,乔良伟,等.白藜芦醇抑制肾移大鼠肾损伤[J].基础医学与临床, 2021, 41: 854-858. [5] McIlroy D, Peltier C, Nguyen ML, et al. Quantification of apobec3 mutation rates affecting the vp1 gene of BK polyomavirus in vivo[J]. Viruses, 2022, 14: 1-10. doi: 10.3390/v14092077. [6] Kotton CN, Kamar N, Wojciechowski D, et al. The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation[J]. Transplantation, 2024, 108: 1834-1866. doi: 10.1097/TP.0000000000004976. [7] Xu C, Chen S, Chen J, et al. Dual roles of BK polyomavirus in promoting urothelial carcinoma progression via regulating cldn1[J]. Biomark Res, 2024, 12: 9. doi: 10.1186/s40364-024-00564-2. [8] 王琼,董倩兰,朱燕亭,等.桔梗皂苷D减轻大鼠肾缺血/再灌注损伤[J]. 基础医学与临床, 2023, 43: 1222-1228. [9] Sato N, Mori KP, Sakai K, et al. Exploring the mechanism of BK polyomavirus-associated nephropathy through consen-sus gene network approach[J]. PLoS One, 2023, 18: e0282534. doi: 10.1371/journal.pone.0282534. [10] Sorin MN, Di Maio A, Silva LM, et al. Structural and functional analysis of natural capsid variants suggests sialic acid-independent entry of BK polyomavirus[J]. Cell Rep, 2023, 42: 112114. doi: 10.1016/j.celrep.2023.112114. [11] Laine HK, Waterboer T, Syrjanen K, et al. Seropreva-lence of polyomaviruses BK and JC in finnish women and their spouses followed-up for three years[J]. Sci Rep, 2023, 13: 879. doi: 10.1038/s41598-023-27850-7. [12] Wang Y, Yan S, Liu Y, et al. Dynamic viral integration patterns actively participate in the progression of BK polyomavirus-associated diseases after renal transplantation[J]. Am J Transplant, 2023, 23: 1694-1708. doi: 10.1016/j.ajt.2023.07.014. [13] Haller J, Diebold M, Leuzinger K, et al. Urine cxcl10 to assess BK polyomavirus replication after kidney transplantation[J]. Transplantation, 2023, 107: 2568-2574. doi: 10.1097/TP.0000000000004712. [14] Brustikova K, Ryabchenko B, Liebl D, et al. BK polyomavirus infection of bladder microvascular endothelial cells leads to the activation of the cgas-sting pathway[J]. J Med Virol, 2024, 96: e70038. doi: 10.1002/jmv.70038. [15] Rochford R, Moreno JP, Peake ML, et al. Enhancer dependence of polyomavirus persistence in mouse kidneys[J]. J Virol, 1992, 66: 3287-3297. doi: 10.1128/JVI.66.6.3287-3297.1992. [16] Yang JF, You J. Regulation of polyomavirus transcription by viral and cellular factors[J]. Viruses, 2020, 12: 1-10. doi: 10.3390/v12101072. [17] Lorentzen EM, Henriksen S, Rinaldo CH. Modelling BK polyomavirus dissemination and cytopathology using polarized human renal tubule epithelial cells[J]. PLoS Pathog, 2023, 19: e1011622. doi: 10.1371/journal.ppat.1011622. [18] Redondo N, Rodriguez-Goncer I, Parra P, et al. Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation[J]. Sci Rep, 2022, 12: 11338. doi: 10.1038/s41598-022-15406-0. [19] Nog R, Mopidevi B, Sivankutty I, et al. Bk polyomavirus microrna in kidney transplant recipient[J]. Transplant Proc, 2024, 56: 1493-1495. doi: 10.1016/j.transproceed.2024.03.044. [20] Wilhelm M, Kaur A, Geng A, et al. Donor variability and pd-1 expression limit BK polyomavirus-specific T-cell function and therapy[J]. Transplantation, 2025, 1: 1-6. doi: 10.1097/TP.0000000000005399. [21] Yang F, Chen X, Zhang H, et al. Single-cell transcript-ome identifies the renal cell type tropism of human BK polyomavirus[J]. Int J Mol Sci, 2023, 24: 1-10. doi: 10.3390/ijms24021330. [22] Helle F, Aubry A, Morel V, et al. Neutralizing antibodies targeting BK polyomavirus: clinical importance and therapeutic potential for kidney transplant recipients[J]. J Am Soc Nephrol, 2024, 35: 1425-1433. doi: 10.1681/ASN.0000000000000457. [23] Siripoon T, Apiwattanakul N, Mongkolrattanakul P, et al. Clinical and immunological characteristics for BK polyomavirus-associated nephropathy after kidney transplanta-tion[J]. Immun Inflamm Dis, 2023, 11: e956. doi: 10.1002/iid3.956. [24] Gately R, Milanzi E, Lim W, et al. Incidence, risk factors, and outcomes of kidney transplant recipients with BK polyomavirus-associated nephropathy[J]. Kidney Int Rep, 2023, 8: 531-543. doi: 10.1016/j.ekir.2022.12.020. [25] Zhou X, Zhu C, Li H. BK polyomavirus: latency, reactivation, diseases and tumorigenesis[J]. Front Cell Infect Microbiol, 2023, 13: 1263983. doi: 10.3389/fcimb.2023.1263983. |